A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria

• Males and females aged 12 to <18 years for Cohort 1. Males and females aged 4 to <12 years for Cohort 2.

• Plaque psoriasis for at least 6 months.

• Moderate to severe disease.

• Candidate for phototherapy or systemic therapy.

• Must have completed the Week 52 treatment period in Part A or B for long-term extension (LTE) period.

Exclusion Criteria

• Participants weighing ≤ 30.0 kg at screening for Cohort 1 (age 12 to < 18 years), Part A and Part B. Participants weighing ≤ 18.0 kg at screening for Cohort 2 (age 4 to < 12 years), Part A and Part B.

• Other forms of psoriasis.

• History of recent infection.

• Prior exposure to deucravacitinib (BMS-986165) or active comparator.

• Evidence of active TB for LTE period.

• Other protocol-defined inclusion/exclusion criteria apply.